Search
forResearch 10 of 1000+
- Immune response involving the bulge region in addition to telogen conversion contributes to hair loss in a case of atypical drug-induced hypersensitivity syndrome
- Stimuli-responsive hydrogels for radiation-induced skin injury: from passive barriers to autonomous drug delivery systems
- Photo-responsive fibers as artificial hairs in an in-vitro model for transdermal drug delivery
- Drug‐Free Ultrasound‐Responsive Mechanoluminescent Suture Enables On‐Demand Antibacterial Therapy and Enhanced Healing of Infected Wounds
- Smart Responsive Microneedles for Controlled Drug Delivery
- Response to the letter to the editor; Androgenetic alopecia; drug safety and therapeutic strategies
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
- Preparation of ROS‐Responsive Drug‐Loaded Particles and Microneedles for Diabetic Wounds Healing
- Response to “The Role of Patient‐ and Drug‐Related Factors in Oral Minoxidil and Pericardial Effusion: Analyses of Data From the United States Food and Drug Administration Adverse Event Reporting System”
Community 10 of 117
- How is it possible for someone to be a non responder to ORAL minoxidil?
- Can liver problems be associated with response to the oral minoxidil?
- Fin/Dut and Metabolism Speeds…
- will pp405 be able to bring my lost temple area back to the game?
- Drug restored full hair in 23% and over 80% of hair in 55% in 6 months
- Drug-free hair transplant while waiting for future treatments to become available to public: stupid or good plan?
- Arthritis drug restores 100% hair on 1 in 5 alopecia patients in global trial
- A miraculous drug that regrows body parts.
- PP405 Drug in Action: Picture From Official Company Website
- HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia